Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Apr 16;22(8):4110.
doi: 10.3390/ijms22084110.

JDP2, a Novel Molecular Key in Heart Failure and Atrial Fibrillation?

Affiliations
Review

JDP2, a Novel Molecular Key in Heart Failure and Atrial Fibrillation?

Gerhild Euler et al. Int J Mol Sci. .

Abstract

Heart failure (HF) and atrial fibrillation (AF) are two major life-threatening diseases worldwide. Causes and mechanisms are incompletely understood, yet current therapies are unable to stop disease progression. In this review, we focus on the contribution of the transcriptional modulator, Jun dimerization protein 2 (JDP2), and on HF and AF development. In recent years, JDP2 has been identified as a potential prognostic marker for HF development after myocardial infarction. This close correlation to the disease development suggests that JDP2 may be involved in initiation and progression of HF as well as in cardiac dysfunction. Although no studies have been done in humans yet, studies on genetically modified mice impressively show involvement of JDP2 in HF and AF, making it an interesting therapeutic target.

Keywords: atrial fibrillation; heart failure; remodeling; transcription factor.

PubMed Disclaimer

Conflict of interest statement

Authors have no conflict to disclose.

Figures

Figure 1
Figure 1
Overview about cardiac JDP2 effects. Summarized are results of studies about JDP2 effects in the heart and isolated cardiomyocytes.
Figure 2
Figure 2
Potential mechanisms contributing to heart failure and atrial fibrillation in JDP2 mice.

Similar articles

Cited by

References

    1. Bragazzi N., Zhong W., Shu J., Abu Much A., Lotan D., Grupper A., Younis A., Dai H. Burden of heart failure and underlying causes in 195 countries and territories from 1990 to 2017. Eur. J. Prev. Cardiol. 2021:zwaa147. doi: 10.1093/eurjpc/zwaa147. - DOI - PubMed
    1. Staerk L., Sherer J.A., Ko D., Benjamin E.J., Helm R.H. Atrial Fibrillation: Epidemiology, Pathophysiology, and Clinical Outcomes. Circ. Res. 2017;120:1501–1517. doi: 10.1161/CIRCRESAHA.117.309732. - DOI - PMC - PubMed
    1. Hindricks G., Potpara T., Dagres N., Arbelo E., Bax J.J., Blomström-Lundqvist C., Boriani G., Castella M., Dan G.A., Dilaveris P.E., et al. ESC Scientific Document Group. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS) Eur. Heart J. 2021;42:373–498. doi: 10.1093/eurheartj/ehaa612. - DOI - PubMed
    1. Tsai M.-H., Wuputra K., Lin Y.-C., Lin C.-S., Yokoyama K.K. Multiple functions of the histone chaperone Jun dimerization protein 2. Gene. 2016;590:193–200. doi: 10.1016/j.gene.2016.03.048. - DOI - PMC - PubMed
    1. Aronheim A., Zandi E., Hennemann H., Elledge S.J., Karin M. Isolation of an AP-1 repressor by a novel method for detecting protein–protein interactions. Mol. Cell. Biol. 1997;17:3094–3102. doi: 10.1128/MCB.17.6.3094. - DOI - PMC - PubMed